Breaking News
FONT-SIZE Plus   Neg
Share SHARE

Amgen's PCSK9 Inhibitor Lowers LDL Cholesterol Up To 81%

RELATED NEWS
Trade AMGN now with 

Amgen Inc. (AMGN: Quote) Sunday reported positive results from phase 1b study of AMG 145, an investigational PCSK9 inhibitor, in patients with high cholesterol who were taking statins. The study revealed that multiple doses of the drug significantly reduced LDL, or bad cholesterol, by up to 81 percent compared to placebo in patients on low to moderate doses of statins.

AMG 145 is a fully human monoclonal antibody that inhibits PCSK9, a protein that reduces the liver's ability to remove LDL-C from the blood. High LDL cholesterol is the main contributor to the risk of developing cardiovascular disease.

In the 51-patient study, the subjects who received AMG 145 every two weeks in combination with low to moderate doses of statins had LDL reductions of up to 75 percent versus placebo at sixth week.

Meanwhile, the subjects who received AMG 145 in combination of low to moderate doses of statins every four weeks showed up to a 66 percent reduction in LDL at eighth week.

Patients on high doses of statins who received AMG 145 every two weeks had a reduction in LDL of up to 63 percent versus placebo at sixth week, the company said.

Click here to receive FREE breaking news email alerts for Amgen Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Before heading to New York for meetings with other world leaders at the United Nations, President Barack Obama delivered a statement on Tuesday regarding U.S. airstrikes in Syria. Obama highlighted the fact that the U.S. was joined in the attack by Saudi Arabia, the United Arab Emirates, Jordan, Bahrain, and Qatar. After recovering from an initial move to the downside, stocks have shown a lack of direction over the course of the trading day on Tuesday. The choppy trading comes on the heels of the notable pullback seen in the previous session. With lawmakers failing to address corporate tax reform before adjourning for the campaign season, the Treasury Department announced Monday that it is taking targeted action to reduce the tax benefits of corporate tax inversions.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.